Raashid Ahmed Luqmani

Raashid Ahmed Luqmani's AcademicInfluence.com Rankings

Engineering

#6016

World Rank

#7311

Historical Rank

Electrical Engineering

#1737

World Rank

#1836

Historical Rank

engineering Degrees

Raashid Ahmed Luqmani

Computer Science

#7802

World Rank

#8209

Historical Rank

Computational Linguistics

#1635

World Rank

#1652

Historical Rank

Machine Learning

#3013

World Rank

#3050

Historical Rank

Artificial Intelligence

#3308

World Rank

#3356

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Raashid Ahmed Luqmani's Degrees

Masters Electrical Engineering Stanford University
Bachelors Computer Engineering University of California, Berkeley

Why Is Raashid Ahmed Luqmani Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Raashid Ahmed Luqmani's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. (2013) (4083)
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. (1994) (1035)
EULAR recommendations for the management of primary small and medium vessel vasculitis (2008) (933)
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. (2010) (905)
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016) (891)
Modification and validation of the Birmingham Vasculitis Activity Score (version 3) (2008) (755)
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. (2005) (731)
Long-term patient survival in ANCA-associated vasculitis (2010) (707)
EULAR recommendations for the management of large vessel vasculitis (2008) (625)
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis (2006) (563)
2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative (2012) (531)
Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. (1997) (510)
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis (2017) (509)
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. (2002) (503)
2018 Update of the EULAR recommendations for the management of large vessel vasculitis (2019) (459)
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). (2001) (416)
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force (2007) (378)
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up (2011) (356)
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. (2016) (320)
BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. (2007) (313)
British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). (2006) (309)
Nomenclature of Cutaneous Vasculitis (2018) (296)
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC (2018) (278)
2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. (2012) (231)
BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. (2014) (226)
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (222)
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. (2015) (215)
Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. (2015) (212)
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. (2010) (205)
Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. (1997) (200)
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). (2005) (193)
Relapses in patients with a systemic vasculitis. (1993) (191)
The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis (2012) (189)
British Society for Rheumatology and british health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). (2006) (189)
Mortality in systemic vasculitis: a systematic review. (2008) (173)
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (163)
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis (2010) (159)
ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS) (2013) (153)
A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis (2011) (152)
The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. (2015) (137)
Necrotic granulomatous pseudotumours in bilateral resurfacing hip arthoplasties: evidence for a type IV immune response (2008) (132)
Damage occurs early in systemic vasculitis and is an index of outcome. (1997) (125)
European therapeutic trials in ANCA‐associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl‐Cr93‐1078) (1995) (125)
Design of the Wegener's Granulomatosis Etanercept Trial (WGET). (2002) (118)
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. (2012) (117)
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. (2020) (116)
Diagnosis and management of ANCA associated vasculitis (2012) (112)
Disease assessment and management of the vasculitides. (1997) (108)
Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS) (2012) (107)
Classical versus non-renal Wegener's granulomatosis. (1994) (105)
Dermatological Addendum to the 2012 International Chapel Hill Consensus Conference Nomenclature of Vasculitides (2017) (104)
The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist (2018) (103)
Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. (1994) (102)
Hydroxychloroquine retinopathy (2017) (102)
Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). (1998) (102)
The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis (2011) (99)
Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis (2008) (97)
Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. (2015) (96)
Development of comprehensive disease assessment in systemic vasculitis. (2007) (94)
Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. (2011) (89)
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. (2011) (89)
Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? (2017) (88)
Mortality in Wegener's granulomatosis: a bimodal pattern. (2011) (82)
Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda (2011) (82)
The characterisation and determinants of quality of life in ANCA associated vasculitis (2013) (78)
The diagnostic value of anti-neutrophil cytoplasmic antibody testing in a routine clinical setting. (2001) (77)
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study (2019) (73)
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis (2022) (69)
Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia (2020) (67)
Health‐related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody–associated vasculitis (2011) (66)
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (2008) (63)
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis (2020) (62)
Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis (2020) (61)
Current state of tumour necrosis factor α blockade in Wegener’s granulomatosis (2005) (60)
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis (2022) (60)
The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis (2018) (57)
The validity of surrogate markers in rheumatic disease. (1993) (57)
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis (2022) (56)
A Multicenter, Randomized, Placebo‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis (2019) (56)
Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. (2002) (56)
Patient-reported Outcomes in Polymyalgia Rheumatica (2012) (55)
Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis (2011) (54)
Giant cell arteritis: Current treatment and management. (2015) (54)
Ocular manifestations of classical and limited Wegener's granulomatosis. (1993) (53)
Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index (2010) (52)
VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis. (1995) (52)
The future of damage assessment in vasculitis. (2007) (51)
The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice (2017) (51)
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis (2022) (51)
Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. (2015) (50)
Development of comprehensive disease assessment in systemic vasculitis (2006) (49)
Explaining fatigue in ANCA-associated vasculitis. (2013) (49)
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. (2020) (48)
Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis. (2006) (48)
Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis (2019) (48)
Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2017) (47)
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. (2005) (46)
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. (2011) (44)
Systemic vasculitis--is it time to reclassify? (2011) (44)
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. (2010) (43)
Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis (2019) (43)
Update on the classification of vasculitis. (2013) (42)
An approach to the diagnosis and management of systemic vasculitis (2010) (41)
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire (2018) (41)
Damage Assessment in ANCA-Associated Vasculitis (2012) (41)
The RUDY study platform – a novel approach to patient driven research in rare musculoskeletal diseases (2016) (40)
Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. (2014) (39)
ROS-producing immature neutrophils in giant cell arteritis are linked to vascular pathologies (2020) (39)
State of the Art in the Treatment of Systemic Vasculitides (2014) (39)
Pseudoporphyria and Nonsteroidal Antiinflammatory Agents in Children with Juvenile Idiopathic Arthritis (2000) (39)
Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients (2010) (38)
Assessment of damage in vasculitis: expert ratings of damage. (2009) (37)
The Phenotype of Circulating Follicular-Helper T Cells in Patients with Rheumatoid Arthritis Defines CD200 as a Potential Therapeutic Target (2012) (37)
Maternal Stressors, Maternal Wellbeing and Children's Wellbeing in the Context of Juvenile Idiopathic Arthritis (2002) (37)
Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody–associated vasculitis (2017) (37)
A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem). (1999) (37)
Pulmonary-renal syndromes: an update for respiratory physicians. (2011) (35)
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis (2022) (35)
Physiotherapy for children with hypermobility syndrome (2000) (35)
Assessing disease activity in the systemic vasculitides (2002) (33)
Clinical associations of renal involvement in ANCA-associated Vasculitis. (2020) (33)
Diagnosis of giant cell arteritis. (2020) (33)
Current Status of Outcome Measure Development in Vasculitis (2014) (32)
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9 (2009) (32)
Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis (2017) (31)
Clinical features and structured clinical evaluation of vasculitis. (2018) (30)
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis (2022) (30)
Posterior scleritis--an unusual manifestation of Cogan's syndrome. (1994) (29)
Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2020) (29)
Comparison of interferon-{gamma} release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study (2010) (28)
Hydroxychloroquine retinopathy: an emerging problem (2017) (28)
The association of vascular risk factors with visual loss in giant cell arteritis (2016) (28)
How to diagnose and treat secondary forms of vasculitis. (2005) (28)
The RUDY study: using digital technologies to enable a research partnership (2017) (28)
Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). (2006) (27)
Cardiovascular involvement in primary systemic vasculitis. (2009) (27)
Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort (2019) (26)
Is rheumatoid factor useful in primary care? A retrospective cross-sectional study (2013) (25)
Outpatient assessment of systemic vasculitis. (2007) (25)
The role of biologic therapies in the management of systemic vasculitis. (2006) (24)
Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study (2016) (24)
Listeria monocytogenes infection in a prosthetic knee joint in rheumatoid arthritis. (1990) (24)
Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. (2020) (24)
Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study (2021) (24)
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? (2005) (23)
Two cases of 'Wegener's tuberculosis'. (1993) (23)
Medical student appraisal of interactive computer‐assisted learning programs embedded in a general pathology course (2000) (23)
Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody–associated Vasculitis Using the OMERACT Process (2015) (23)
Azathioprine, cyclophosphamide and chlorambucil. (1990) (23)
Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward? (2007) (22)
Introduction to, and classification of, the systemic vasculitides. (2001) (22)
Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. (2019) (22)
Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides (2019) (22)
Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts (2017) (21)
Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure (2018) (21)
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. (2010) (21)
Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS). (2017) (21)
Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. (2007) (21)
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis (2020) (21)
Developing multidisciplinary guidelines for the management of early rheumatoid arthritis. (2008) (21)
The European Vasculitis Society 2016 Meeting Report (2017) (20)
Maintenance of clinical remission in ANCA-associated vasculitis (2013) (20)
SAT0286 Paediatric Vasculitis Damage Index: A New Tool for Standardised Disease Assessment (2014) (20)
Long-term damage to the ENT system in Wegener’s granulomatosis (2011) (20)
European Headache Federation recommendations for neurologists managing giant cell arteritis (2020) (19)
Diagnosis and assessment of systemic vasculitis. (2002) (19)
Textbook of orthopaedics, trauma, and rheumatology / (2008) (19)
Large vessel vasculitides: update for the cardiologist (2012) (19)
Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis. (2019) (18)
The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. (2019) (18)
Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. (2012) (18)
Giant cell arteritis: new concepts, treatments and the unmet need that remains. (2018) (18)
Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. (2005) (18)
Systemic cytokine measurements: their role in monitoring the response to therapy in patients with rheumatoid arthritis. (1994) (17)
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in "non-renal" AbCA-associated vasculitis. (2002) (17)
Rheumatoid constrictive pericarditis. (1997) (17)
Optimisation of Cyclophosphamide Therapy in Systemic Vasculitis (1998) (17)
OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis (2017) (16)
Birmingham Vasculitis Activity Score (1993) (16)
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. (2020) (15)
Assessment of systemic vasculitis. (2008) (15)
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. (2020) (15)
Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS (2009) (14)
Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases. (2014) (14)
Inner ear deafness in Wegener's granulomatosis. (1991) (14)
Is vascular endothelial growth factor a useful biomarker in giant cell arteritis? (2017) (14)
2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis (2022) (14)
Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. (2020) (14)
Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss (2020) (13)
Acute pancreatitis with pseudocyst formation in a patient with polyarteritis nodosa. (2005) (13)
Clinical and biological assessment in systemic necrotizing vasculitides. (2006) (13)
S100A12 Serum Levels and PMN Counts Are Elevated in Childhood Systemic Vasculitides Especially Involving Proteinase 3 Specific Anti-neutrophil Cytoplasmic Antibodies (2018) (13)
Treatment of vasculitis in rheumatoid arthritis. (1994) (13)
Pharmacotherapy of vasculitis (2009) (12)
The role of neutrophils in rheumatic disease-associated vascular inflammation (2022) (12)
Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. (2020) (12)
Outcome in small-vessel systemic vasculitis. (2006) (11)
077. CLASSIFICATION CRITERIA FOR LARGE-VESSEL VASCULITIS (2019) (11)
Disease assessment in systemic vasculitis. (2015) (11)
Discontinuation of therapies in vasculitis. (2013) (11)
Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future (2020) (11)
Necrotizing vasculitis--relapse despite cytotoxic therapy. (1993) (10)
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis (2021) (10)
Cryofibrinogenaemia—a neglected disease (2016) (10)
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal (2014) (10)
Comparison of disease activity measures for ANCA-associated vasculitis. (2004) (10)
ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS (1994) (9)
Outcome measures in ANCA-associated vasculitis. (2010) (9)
Evaluation of vasculitis disease activity in Europe. (2001) (9)
110. CLASSIFICATION CRITERIA FOR THE ANCA-ASSOCIATED VASCULITIDES (2019) (9)
Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial (2009) (9)
Early development of new cardiovascular risk factors in the systemic vasculitides. (2019) (9)
2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis (2022) (9)
Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV) (2003) (9)
Treat-to-target in vasculitis: is this a sensible approach? (2012) (8)
EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis (2007) (8)
DISEASE‐MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: CURRENT CONCEPTS (1994) (7)
Time to focus on outcome assessment tools for childhood vasculitis (2011) (7)
Eular recommendations for vasculitis (2007) (7)
Assessment of Disease Activity and Damage (2014) (7)
Missing laboratory test data in electronic general practice records: analysis of rheumatoid factor recording in the clinical practice research datalink (2015) (7)
Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink. (2015) (7)
2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis (2022) (7)
A comparison of two formulations of indomethacin ('Flexin Continus' tablets and 'Indocid' capsules) in the treatment of rheumatoid arthritis. (1990) (7)
Giant Cell Arteritis and Takayasu Arteritis: Are they a different spectrum of the same disease? (2015) (7)
Vasculitis integrated total assessment log (VITAL): A system for clinical evaluation of vasculitis. (1996) (6)
2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis (2022) (6)
Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update (2013) (6)
Pulmonary Involvement in Primary Systemic Vasculitides. (2021) (6)
Immunopharmacology of Vasculitic Syndromes (1992) (6)
Is it possible to offer evidence-based treatment for systemic vasculitis?: Editorial review (2000) (6)
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort (2013) (6)
NEGATIVE RHEUMATOID FACTOR IN PRIMARY CARE DELAYS REFERRAL OF PATIENTS WITH RHEUMATOID ARTHRITIS (2014) (6)
Reuma.pt/vasculitis – the Portuguese vasculitis registry (2020) (5)
Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis (2019) (5)
EARLY HALO SIGN FEATURES ON ULTRASOUND EXAMINATION OF TREATED PATIENTS WITH GIANT CELL ARTERITIS (2015) (5)
RHEUMATOID FACTOR TESTING IN SPANISH PRIMARY CARE COSTS (sic)1432 PER TRUE POSITIVE CASE OF RHEUMATOID ARTHRITIS; A STUDY USING ELECTRONIC DATA FROM THE INFORMATION SYSTEM FOR THE DEVELOPMENT OF RESEARCH IN PRIMARY CARE (2015) (5)
Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv) (2003) (5)
United Kingdom & Ireland Vasculitis Registry - Cross-Sectional Data on the First 1085 Patients (2014) (5)
The use of ultrasound in the management of large-vessel vasculitis: an evolving concept. (2018) (5)
Different Disease Endotypes in Phenotypically Similar Vasculitides Affecting Small-to-Medium Sized Blood Vessels (2021) (5)
Efficacy and Safety of Belimumab in Combination with Azathioprine for Remission Maintenance in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: A Multicenter Randomized, Placebo-Controlled Study (2017) (4)
083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU’S ARTERITIS AND GIANT CELL ARTERITIS (2019) (4)
Measuring disease activity and outcomes in clinical studies. (2002) (4)
UK & IRELAND VASCULITIS REGISTRY (UKIVAS): CROSS-SECTIONAL DATA ON THE FIRST 556 PATIENTS (2014) (4)
Towards diagnostic criteria for the ANCA-associated vasculitides. (2007) (4)
An audit of the use of hydroxychloroquine in rheumatology clinics (2018) (4)
Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease. (2020) (4)
WS2_1 The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV) (2017) (4)
FRI0464 Development of the Classification Criteria for GIANT Cell Arteritis in the Diagnostic and Classification Criteria for Vasculitis Study: A Pilot Study Using A Panel Review Methodology (2014) (4)
Making the most of the waiting room: Electronic patient engagement, a mixed methods study (2018) (4)
Disease activity in paediatric vasculitis: development of a generic assessment tool - PVAS (2011) (3)
Advances in the classification of primary systemic vasculitis (2009) (3)
THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS (2012) (3)
An unusual cause of death in Wegener’s granulomatosis (2006) (3)
A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA). (2000) (3)
Updating the BSR Guidelines for Anti-TNF therapy in Adult RA (again) (2006) (3)
STANDARIZATION OF DISEASE ASSESMENT IN SYSTEMIC VASCULITIS: USE OF A NOVEL WEB-BASED SOFTWARE TRAINING APPLICATION (2014) (3)
CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) (2004) (3)
Long-term survival of ANCA-associated vasculitis (2009) (3)
A hidden lung cancer in a patient with granulomatosis with polyangiitis (2020) (3)
THE VASCULITIS DAMAGE INDEX (VDI) (1995) (3)
Comprar Textbook of Orthopaedics, Trauma and Rheumatology | Raashid Luqmani | 9780723433897 | Mosby (2008) (3)
Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting (2001) (3)
Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis - a Pediatric Vasculitis Initiative (PedVas) Study (2017) (3)
Oral Abstracts 1: Connective Tissue DiseaseO1. Long-Term Outcomes of Children Born to Mothers with SLE (2013) (3)
Cyclophosphamide and systemic vasculitis. (1993) (3)
Functional outcome vs damage in systemic vasculitis (1996) (3)
OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis (2016) (3)
Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus (2007) (3)
Autoantibodies Against Lysosome Associated Membrane Protein-2 (LAMP-2) in Pediatric Chronic Primary Systemic Vasculitis (2021) (3)
Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary. (2020) (3)
Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements. (2019) (2)
Pulse versus daily oral CyP for induction of remission in ANCA-associated vasculitis. A European, multi-centre randomized controlled trial: long-term follow-up (2011) (2)
PRELIMINARY ANALYSIS OF HISTOLOGICAL FINDINGS IN GCA BIOPSY-POSITIVE PATIENTS RECRUITED INTO A LARGE MULTICENTRE STUDY OF TEMPORAL ARTERY ULTRASOUND VERSUS BIOPSY IN THE DIAGNOSIS OF GIANT CELL ARTERITIS (2015) (2)
THU0286 MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS (2019) (2)
90 – Polyarteritis Nodosa and Related Disorders (2013) (2)
The Diagnostic Accuracy Of Rheumatoid Factor Testing In Primary Care (2013) (2)
Test Data in General Practice Are Not Missing at Random - Can We Identify When They Are? (2013) (2)
Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV) (2008) (2)
Serum Vascular Endothelial Growth Factor is Selectively Upregulated in Patients with Biopsy-Proven Giant Cell Arteritis (2014) (2)
Comprar Rheumatoid Arthritis | Raashid Luqmani | 978-0-19-955675-5 | Oxford University Press (2010) (2)
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides (2013) (2)
Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis (2020) (2)
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update (2023) (2)
Response to: ‘Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues’ by Ghajari and Sabour (2020) (2)
of large vessel vasculitis EULAR recommendations for the management (2009) (2)
RE-APPRAISAL OF THE 1990 AMERICAN COLLEGE OF RHEUMATOLOGY CLASSIFICATION CRITERIA FOR SYSTEMIC VASCULITIS: ANALYSIS OF DATA FROM THE DIAGNOSTIC AND CLASSIFICATION CRITERIA IN VASCULITIS STUDY (2015) (2)
Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis (2015) (2)
PREDICTORS OF DELAY IN DIAGNOSIS OF GIANT CELL ARTERITIS AND ANTINEUTROPHIL CYTOPLASM ANTIBODY ASSOCIATED VASCULITIDES: ANALYSIS OF DATA FROM THE DIAGNOSTIC & CLASSIFICATION CRITERIA IN VASCULITIS STUDY (2015) (2)
Behcet's disease: basic and clinical aspects (1993) (2)
Giant cell arteritis: new concepts, treatments and the unmet need that remains. (2019) (2)
SY4_1 Giant cell arteritis (GCA) and Takayasu arteritis (TAK): a spectrum within the same disease or not? A report from the DCVAS project. (2017) (1)
LB943 Cutaneous manifestations of ANCA-associated vasculitis are common, varied, and associated with systemic disease (2017) (1)
Primary and secondary glomerulonephritis I (2012) (1)
Update on the use of biologics in primary systemic vasculitides (2007) (1)
A comparison of two formulations of indomethacin ('Flexin Continus' tablets and 'Indocid' capsules) in the treatment of osteoarthritis. (1990) (1)
Prevalence and associations of peripheral neuropathy at disease-onset in ANCA-associated vasculitides: Data from DCVAS study (2018) (1)
FRI0284 RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS (2019) (1)
The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK (2013) (1)
BSR guideline on diagnosis and treatment of giant cell arteritis (2020) (1)
MEPOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A PHASE III RANDOMISED, PLACEBO-CONTROLLED TRIAL (2017) (1)
ANCA-associated vasculitis: Where can we go from here? (2010) (1)
BIMODAL MORTALITY RISK IN WEGENER'S GRANULOMATOSIS (2009) (1)
SAT0190 A Diagnostic Protocol for GIANT Cell Arteritis (GCA) Using Ultrasound Assessment (2014) (1)
HISTOLOGY FINDINGS IN GIANT CELL ARTERITIS (GCA) AND THEIR RELATIONSHIP WITH THE ULTRASOUND RESULTS: ANALYSIS OF DATA FROM THE TABUL STUDY (TEMPORAL ARTERY BIOPSY VS ULTRASOUND IN DIAGNOSIS OF GIANT CELL ARTERITIS) (2017) (1)
Chapter 90 – Polyarteritis Nodosa and Related Disorders (2017) (1)
CONTROLLED TRIAL OF PULSE VS CONTINUOUS CYCLOPHOSPHAMIDE (CY) AND PREDNISOLONE (P) IN THE TREATMENT OF SYSTEMIC VASCULITIS (1993) (1)
Long-term follow up of EUVAS studies (2007) (1)
Tumor Necrosis Factor–Blocking Agents in Polymyalgia Rheumatica and Giant Cell Arteritis (2008) (1)
Assessment of damage in vasculitis: expert ranking of items of damage (2007) (1)
P186 Efficacy and safety of rituximab in the treatment of systemic vasculitis: experience at a single centre (2020) (1)
Collection, processing and storage of biopsy samples (2016) (1)
P10. Review of the expert panel methodology in the diagnostic and classification criteria for vasculitis study: a pilot study (2014) (1)
Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV). (2012) (1)
Methotrexate (MTX) failed to control giant cell arteritis (GCA) (2001) (1)
Disease assessment in systemic vasculitis (2004) (1)
MEASUREMENT OF DAMAGE IN SYSTEMIC VASCULITIS (2010) (1)
A DIAGNOSTIC PROTOCOL FOR GIANT CELL ARTERITIS USING ULTRASOUND ASSESSMENT (2015) (1)
PREDICTORS OF AORTIC ANEURYSMS FOR GIANT CELL ARTERITIS SUBJECTS (2013) (1)
Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease (1994) (1)
035 Aortic dissection secondary to giant cell arteritis in a patient on tocilizumab for established seronegative rheumatoid arthritis (2018) (1)
Cardiovascular outcomes in ANCA associated vasculitis (2008) (1)
O25 Catastrophic antiphospholipid crisis triggered by anticoagulant switch (2021) (1)
The systemically ill patient (2013) (1)
Speaker Abstracts (SP01–SP50) (2012) (1)
SAT0619-HPR AN AUDIT OF GLUCOCORTICOID PRESCRIPTION IN PATIENTS WITH GIANT CELL ARTERITIS (2020) (1)
Can We Identify Patients with Microscopic Polyangiitis Who Are at Risk of Relapse? (2012) (1)
The provisional OMERACT ultrasonography score for giant cell arteritis (2022) (1)
DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV) (2003) (1)
284 Differences in Early Damage Patterns in Various Forms of Primary Systemic Vasculitis (2016) (1)
Vasculitis: an update. (2014) (1)
Vasculitis [232–238] Primary Systemic Vasculitis: A 10 Year True to Life Study from a North London District General Hospital (2010) (1)
CUTANEOUS MANIFESTATIONS OF ANCA-ASSOCIATED VASCULITIS (2016) (1)
Pleural Wegener’s granulomatosis: a rare presentation (2009) (1)
Prospective clinical trial of Gusperimus (deoxyspergualin) in refractory Wegener's granulomatosis (2007) (1)
Chapter 9 Surgical management of rheumatoid arthritis: introduction and spinal involvement (2010) (1)
Neural Correlates of Chronic Fatigue in Granulomatosis with Polyangiitis (GPA; Wegener's)-A Functional Magnetic Resonance Imaging (fMRI) Study (2011) (1)
Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials (2000) (1)
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report (2022) (1)
CHRONIC DYSPAREUNIA - SJOGREN SYNDROME - ANOTHER CLINICAL PRESENTATION (1992) (1)
050 IgG4 related disease causing left anterior descending artery stenosis successfully treated with rituximab therapy (2018) (1)
Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary. (2020) (1)
Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis (2015) (1)
FUNCTIONAL ASSESSMENT IN VASCULITIS USING THE SF-36 (1995) (1)
AN HLA-DQ-BETA ASSOCIATED RESTRICTION FRAGMENT LENGTH POLYMORPHISM IN RHEUMATOID-ARTHRITIS (1988) (0)
SP0066 Classification and diagnosis of vasculitis (2013) (0)
Reply (2021) (0)
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial (2023) (0)
AB0607 SELF-MANAGEMENT BEHAVIOURS IN ANCA-ASSOCIATED VASCULITIS: SECONDARY ANALYSIS OF INTERVIEW DATA (2019) (0)
P203 Incidence, characteristics and determinants of severe infections in patients with anti-neutrophil cytoplasm antibody-associated vasculitis receiving rituximab therapy: a single centre study (2021) (0)
Large vessel vasculitis (2020) (0)
Reply to three letters-Betrains-Castaneda-Hemmig for AR-22-0212.R1 and AR-22-0213.R1. (2023) (0)
Response to ‘Comment on: ‘A new era for giant cell arteritis’’ (2019) (0)
MULTIPLE JOINT INTRAARTICULAR TRIAMCINOLONE HEXACETONIDE (IATH) IN JUVENILE CHRONIC ARTHRITIS (JCA) (1992) (0)
Damage is independent of disease activity in systemic vasculitis (1998) (0)
Vasculitis: new therapies changing outcomes (0)
DIAGNOSIS AND ASSESSMENT OF LARGE VESSEL VASCULITIS (2011) (0)
A severe, antineutrophil cytoplasmic antibody associated, anterior segment vasculitis (1994) (0)
Cerebrovascular Disease ? A Clinical Practice Research Datalink Study Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or (2016) (0)
P211 Indirect measurement of central sensitisation as a predictor of response to different drug treatments in patients with inflammatory arthritis in a UK clinical cohort (2020) (0)
271 Interrater and Intrarater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis (2016) (0)
Vasculitis: current issues IP93. Pathogenesis of Vasculitis (2011) (0)
Small- and Medium-Vessel Primary Vasculitis (2019) (0)
SP0044 WIN: VASCULITIS MAINTENANCE TREATMENT (2019) (0)
Development of a paediatric anxiety questionnaire (PAQ) in children with rheumatic diseases (2001) (0)
2021 American College of Rheumatology /European League Against Rheumatism Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis (2021) (0)
THE USE OF THE INTERNET IN WEGENER'S GRANULOMATOSIS PATIENTS (2003) (0)
What proportion of patients in a routine clinic for rheumatoid arthritis fulfil the nice criteria for anti-TNF biologic therapy? (2007) (0)
Chapter 8 Comorbidity and complications of RA (2010) (0)
Modified Birmingham vasculitis activity score for Wegener's granulomatosis (BVAS/WG) - Construct validity. (2000) (0)
I72 Introduction to the Online Training System, and Practical Exercise in Assessing Vasculitis Case Scenarios (2016) (0)
New etiopathogenic knowledge, or politics? Comment on the article by Falk et al Reply (2011) (0)
Calprotectin in systemic vasculitis (2006) (0)
P007 Automating blood monitoring and handover for patients with rheumatic diseases commencing disease-modifying anti-rheumatic drugs (DMARDs) (2023) (0)
Outcome in systemic vasculitis. (1998) (0)
Paediatric rheumatology Performance of the Birmingham Vasculitis Activity Score and Disease Extent Index in childhood vasculitides (2012) (0)
The value of a biologics clinic: Adherence to the BSR guidelines for the use of anti-TNF alpha therapy in rheumatoid arthritis (2008) (0)
i138 Assessment of vasculitis (2018) (0)
Updates on the diagnosis and monitoring of giant cell arteritis (2023) (0)
Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development (2015) (0)
FRI0195 ULTRASONOGRAPHIC HALO SCORE ASSOCIATES WITH INTIMAL HYPERPLASIA IN GIANT CELL ARTERITIS (2020) (0)
Ongoing european research initiatives in systemic vasculitides: The EUVAS program (2005) (0)
How Can We Use Ultrasound in the Diagnosis and Management of Patients with Giant Cell Arteritis (2015) (0)
Full Review Disease assessment in systemic vasculitis (2015) (0)
Cryofibrinogenaemia-a neglected disease.. 2016 Oct 27. pii: kew379. [Epub ahead of print] Review.PMID: 27789759 (2016) (0)
Colour Doppler Ultrasonography Findings in Giant Cell Arteritis (GCA) and Their Relationship with Clinical Manifestations. (2014) (0)
DEVELOPMENT OF AUTOMATED CLINICAL VIGNETTES FOR BIRMINGHAM VASCULITIS ACTIVITY SCORE TRAINING USING DATA FROM DIAGNOSTIC AND CLASSIFICATION CRITERIA IN VASCULITIS STUDY (2015) (0)
HOT SESSION: VASCULITIS TREATMENT (2017) (0)
USE OF A COMPUTERISED SYSTEM TO FACILITATE MANAGEMENT OF AUTOIMMUNE RHEUMATIC DISEASES (2017) (0)
i128 Improving value projects (2018) (0)
A NEGATIVE RHEUMATOID FACTOR RESULT IN PRIMARY CARE SIGNIFICANTLY DELAYS THE TIME TO DIAGNOSIS OF RHEUMATOID ARTHRITIS: A STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK (2015) (0)
The HAVEN study—hydroxychloroquine in ANCA vasculitis evaluation—a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan (2023) (0)
A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital. (2000) (0)
Safety of fast track infliximab infusions "the quick inflix'' (2008) (0)
Chapter 3 Diagnosis and clinical features of rheumatoid arthritis (2010) (0)
OP0142 THE IMPACT OF DISEASE EXTENT AND SEVERITY DETECTED BY QUANTITATIVE ULTRASOUND ANALYSIS IN THE DIAGNOSIS AND OUTCOME OF GIANT CELL ARTERITIS: RESULTS FROM THE TEMPORAL ARTERYBIOPSY VERSUS ULTRASOUND (TABUL) STUDY AND VALIDATION IN AN INDEPENDENT COHORT (2019) (0)
Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis task force (2007) (0)
Training patients to self administer sub-cutaneous methotrexate (SCMTX) (2001) (0)
O09 Ultrasound Compared with Biopsy in the Diagnosis of Suspected Giant Cell Arteritis (2016) (0)
Vasculitis 265. Cryoglobulinemic Vasculitis Secondary to Hepatitis C Infection: Is Prediction of Disease Severity Feasible? (2011) (0)
INCREASED RISK OF CEREBROVASCULAR AND CEREBROVASCULAR DISEASE OUTCOMES IN PATIENTS WITH GIANT CELL ARTERITIS INDEPENDENTLY ASSOCIATED WITH SOCIAL DEPRIVATION (2015) (0)
Multiple joint intra-articular injections of triamcinolone hexacetonide (iath) in juvenile chronic arthritis (jca) (1993) (0)
A DISEASE- SPECIFIC PATIENT-REPORTED OUTCOME FOR ANCA ASSOCIATED VASCULITIS: SCALE STRUCTURE AND MEASUREMENT PROPERTIES OF THE AAV-PRO (2017) (0)
An audit of the use of hydroxychloroquine in rheumatology outpatients clinic (2018) (0)
A computerised system to evaluate patients with rheumatic diseases (2019) (0)
EULAR Recommendations for the Management of Rheumatic Diseases: 2007 Updates (2007) (0)
EP03 An audit of glucocorticoid prescription in patients with giant cell arteritis (2020) (0)
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: Joint procedural recommendation of the EANM, SNMMI, the PET Interest Group (PIG), and endorsed by the ASNC Writing group*: (2018) (0)
A DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME FOR ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: SCALE STRUCTURE AND MEASUREMENT PROPERTIES OF THE ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME MEASURE (2017) (0)
Nomenclature and classification of vascilitis - update on ACR/EULAR classification. (2011) (0)
DEVELOPMENT OF AN ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME MEASURE: IDENTIFICATION OF SALIENT THEMES AND CANDIDATE QUESTIONNAIRE ITEM DEVELOPMENT (2015) (0)
Global Ethnic and Geographic Differences in the Clinical Features of ANCA-Associated Vasculitis (2016) (0)
THE CLINICAL-VALUE OF MEASURING SOLUBLE VCAM, E-SELECTIN AND ICAM-1 IN SLE, SYSTEMIC-SCLEROSIS AND THE SYSTEMIC VASCULITIDES (1992) (0)
P13 An analysis of multidisciplinary care in systemic auto-immune rheumatic disease in a single centre (2020) (0)
FRI0163 Initial assessment of wegener’s granulomatosis – an audit of rheumatological practice (2001) (0)
Assessment of disease activity and damage in the ANCA-associated systemic vasculitides (2012) (0)
P060 Rituximab as third line therapy in IgG4-Related Disease: experience from a multi-centre cohort (2021) (0)
THU0339 United Kingdom Research Registry for Rare Bone, Joint and Blood Vessel Diseases (RUDY): Analysis of the First 133 Patients (2015) (0)
Response to Letter to the Editor by Drs. Yazici and Yazici regarding the 2022 ACR/EULAR Classification Criteria for the ANCA-associated vasculitides. (2022) (0)
Completion of the clinical case report form (2016) (0)
of primary small and medium vessel vasculitis EULAR recommendations for the management (2009) (0)
Sunday, May 11, 2008: Free Communications (2008) (0)
Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy (2016) (0)
Recurrent inflammatory stenosis of the M1 segment: diagnostic and therapeutic considerations (2012) (0)
SP143EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS (2016) (0)
Giant Cell Arteritis (2020) (0)
factors for severe outcomes in patients with systemic vasculitis & COVID-19: a bi-national registry-based cohort study (2021) (0)
P211 Aortitis: clinical experience within a tertiary centre (2021) (0)
Letter to the Editor (Matters Arising) (2008) (0)
HLA-DPB1 is associated with ANCA-associated vasculitis in children. (2022) (0)
Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements (2019) (0)
NEW INSIGHTS INTO THE MANAGEMENT OF SYSTEMIC VASCULITIS (2012) (0)
The vasculitis damage index as a surrogate outcome measure in systemic vasculitis. (1997) (0)
THU0306 Prevalence and characteristics of neuropathy in patients with anca associated vasculitides: data from the dcvas study (2017) (0)
The systemically ill patient Chapter: The systemically ill patient (2013) (0)
FRI0028 Vascular Endothelial Growth Factor as An Aid To Diagnosis of Giant Cell Arteritis (2016) (0)
Reply (1978) (0)
Health-related quality of life in patients with ANCA-associated vasculitis: a pooled analysis of four randomized clinical trials (2009) (0)
Chapter 2 The pathogenesis of rheumatoid arthritis (2010) (0)
082. CLINICAL SUBSETS IN GIANT CELL ARTERITIS (2019) (0)
Do patients with diabetes or rheumatoid arthritis who undergo total hip arthroplasty have a worse outcome compared to patients with uncomplicated osteoarthritis (2007) (0)
Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain (2014) (0)
POS0152-HPR REMOTE CLINICAL MANAGEMENT: INCORPORATING ELECTRONIC ASSESSMENT OF PATIENTS WITH RHEUMATIC DISEASES INTO STANDARD CLINICAL PATHWAYS DURING THE COVID-19 PANDEMIC: A PILOT STUDY (2021) (0)
List of Contributors (2019) (0)
An audit of an emergency rheumatology clinic have we improved our service (2008) (0)
DCVAS ACR/EULAR endorsed study to develop classification and diagnostic criteria for primary systemic vasculitis (2010) (0)
Damage Develops Early and Is Common in Children with Chronic Systemic Vasculitis (2015) (0)
THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS (2011) (0)
OP0055 ULTRASOUND HALO SIGN AS A POTENTIAL MONITORING TOOL FOR PATIENTS WITH GIANT CELL ARTERITIS: A PROSPECTIVE ANALYSIS (2021) (0)
FRI0292 A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIRUKUMAB IN THE TREATMENT OF PATIENTS WITH GIANT CELL ARTERITIS (2019) (0)
Rheumatology Highlights 2001–2002. Edited by P. Bacon. £15.00. Health Press, Oxford, UK, 2002. 92 pages. ISBN: 1‐903‐73414‐2 (2003) (0)
Complementary and alternative medicines (CAM) - Use in patients with rheumatic diseases. (2003) (0)
Health Services Research, Economics and Outcomes Research [86–113]86. What Happens to Patients with Complex Regional Pain Syndrome of Greater than 12 Months’ Duration? (2010) (0)
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. (2023) (0)
Concise report Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis (2014) (0)
Intensive care unit (ICU) outcomes in patients with rheumatic diseases: A retrospective multicenter, international observational study (2001) (0)
THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS (2012) (0)
Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis (2008) (0)
Rare diseases of bones, joints and vessels study (2015) (0)
Correlates of Disease, Function and Self-esteem in Juvenile Idiopathic Arthritis: A cross-sectional pilot study (2000) (0)
ARE WE MEETING THE STANDARDS FOR TEMPORAL ARTERY BIOPSY IN GIANT CELL ARTERITIS (2009) (0)
Validation of a new version of the Birmingbam vasculitis activity score (2008) (0)
P172 Evaluating the use of patient reported outcome measures to assess intra-pandemic psoriatic arthritis disease activity and comparing them with pre-pandemic clinical assessments (2023) (0)
Standardisation of the use of Ultrasound as a diagnostic tool in the diagnosis of Giant Cell Arteritis (GCA) (2012) (0)
Response: Cutaneous manifestations of anti-neutrophil cytoplasmic antibody-associated vasculitis. (2021) (0)
Future treatments in rheumatoid arthritis (2010) (0)
ASSESSMENT OF CURRENT TREATMENT PRACTICE AND UNMET CLINICAL NEEDS IN ANCA-ASSOCIATED VASCULITIS (2017) (0)
CARDIOVASCULAR OUTCOMES ARE WORSE IN MICROSCOPIC POLYANGIITIS COMPARED WITH GRANULOMATOSIS WITH POLYANGIITIS: DATA FROM AN INCEPTION COHORT OF PATIENTS WITH ANTI-NEUTROPHIL CYTOPLASM ANTIBODY ASSOCIATED SYSTEMIC VASCULITIS (2015) (0)
The use of complementary and alternative medicines (CAM) in patients with rheumatic diseases (2003) (0)
UPDATING THE CORE SET OF OUTCOME DOMAINS FOR ANCA-ASSOCIATED VASCULITIS (2017) (0)
I88. Meet The Experts: Vasculitis (2014) (0)
P005 Using novel remote electronic monitoring to measure and manage the Rheumatology Clinic backlog generated by COVID-19 (2023) (0)
Computational modelling of aneurysm risk in giant cell arteritis (GCA) (2013) (0)
Pulmonary Manifestations of Primary Systemic Vasculitides (2017) (0)
Completion of the safety report form (2016) (0)
Scale Structure and Measurement Properties of a Disease Specific Patient-Reported Outcome for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2016) (0)
153. THE 10-YEAR LONG-TERM FOLLOW-UP OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS INCLUDED IN EUROPEAN VASCULITIS SOCIETY RANDOMISED CLINICAL TRIALS SINCE 1995: A SURVIVAL ANALYSIS (2019) (0)
CLASSIFICATION AND DIAGNOSIS OF VASCULITIS (2012) (0)
THU0302 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the tabul study (temporal artery biopsy vs ultrasound in diagnosis of giant cell arteritis) (2017) (0)
OP0063 SINGLE CENTRE EXPERIENCE OF THE CLINICAL SPECTRUM, AETIOLOGIES AND MANAGEMENT OF NON-INFECTIOUS AORTITIS (2021) (0)
USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS (2009) (0)
Do Patients with Giant Cell Arteritis Meet the 2011 United Kingdom Department of Health Guidance on Physical Activity (2015) (0)
OA23 Improving the biopsychosocial assessment and management of patients with fibromyalgia: developing a digital pre-clinic assessment tool (2023) (0)
O17. The UNITED KIGDOM AND Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis (2017) (0)
The Journal of Rheumatology associated Vasculitis − Antineutrophil Cytoplasmic Antibody OMERACT Endorsement of Patient-reported Outcome Instruments in (2017) (0)
RHEUMATOID FACTOR SHOULD NOT BE USED AS A SCREENING TOOL IN PRIMARY CARE (2010) (0)
097 Are we Using too Much Hydroxychloroquine in Patients with Rheumatic Diseases (2016) (0)
Rho Kinase Expression in Giant Cell Arteritis: Validating Phosphorylated Ezrin/Radixin/Moesin Intensity Score to Increase Sensitivity of Temporal Artery Biopsy (2022) (0)
Markers for work disability in ANCA-associated vasculitis (2013) (0)
PTU-100 The role of a multi-regional specialist multi-disciplinary meeting in diagnosis and management of igg4-related disease (2019) (0)
Factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis (2007) (0)
Chapter 4 Disease assessment and monitoring patients for follow up (2010) (0)
Vasculitis (2018) (0)
Activity and Damage (2019) (0)
VASCULAR ENDOTHELIAL GROWTH FACTOR AS AN AID TO DIAGNOSIS OF GIANT CELL ARTERITIS (2016) (0)
The Need for Diagnostic Criteria in Systemic Vasculitis (2011) (0)
A multi-disciplinary approach to igG4 related disease aids in diagnosis and management (2020) (0)
FC 033LONG-TERM FOLLOW-UP OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS INCLUDED IN EUROPEAN VASCULITIS SOCIETY RANDOMIZED CLINICAL TRIALS SINCE 1995: A SURVIVAL ANALYSIS (2021) (0)
E086 Comparing ankylosing spondylitis disease activity during the COVID-19 pandemic using patient-reported outcome measures with face-to-face clinical evaluation of disease scores pre-pandemic (2023) (0)
Chapter 12 Future treatments in rheumatoid arthritis (2010) (0)
THE ROLE OF A STANDARDISED ULTRASOUND PROTOCOL IN THE MANAGEMENT OF GIANT CELL ARTERITIS (GCA) IN ROUTINE CLINICAL PRACTICE (2017) (0)
267. PATIENT PERCEPTIONS OF HEALTH RELATED QUALITY OF LIFE RELATED TO GIANT CELL ARTERITIS AND ITS TREATMENT: AN INTERNATIONAL QUALITATIVE STUDY (2019) (0)
Chapter 7 Multidisciplinary team management (2010) (0)
The prognostic value of BVAS and VDI in ANCA-AAV (2011) (0)
Psychological health in juvenile idiopathic arthritis. (1999) (0)
BLINDNESS IN PATIENTS WITH GIANT CELL ARTERITIS AND ITS ASSOCIATION WITH VASCULAR DISEASE (2016) (0)
P204 An evaluation of a daily fast-track diagnostic ultrasound service for patients with suspected new onset giant cell arteritis during the COVID-19 pandemic (2021) (0)
TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS (2013) (0)
SP0125 HOW TO ASSESS PATIENT WITH SUSPECTED VASCULITIS (2019) (0)
276 The Short-Term Damage Burden in Vasculitis and Vasculitis Mimics as Measured by the Vasculitis Damage Index (2016) (0)
Obituary for Paul Bacon (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Raashid Ahmed Luqmani?

Raashid Ahmed Luqmani is affiliated with the following schools:

Raashid Ahmed Luqmani's Academic­Influence.com Rankings

Raashid Ahmed Luqmani's Degrees

Why Is Raashid Ahmed Luqmani Influential?

Raashid Ahmed Luqmani's Published Works

Published Works

What Schools Are Affiliated With Raashid Ahmed Luqmani?

Raashid Ahmed Luqmani's AcademicInfluence.com Rankings